HR Execs on the Move

R1 RCM

www.r1rcm.com

 
R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers R1`s proven and scalable operating models seamlessly complement a healthcare organization`s infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient experience.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.r1rcm.com
  • 434 West Ascension Way 6th Floor
    Murray, UT USA 84123
  • Phone: 312.324.7820

Executives

Name Title Contact Details
Natalie Fulger
Sr. Director, Talent Acquisition Profile
Hannah Johnson
Revenue Integrity Director Profile
Erika Oddo
Director, Physician Revenue Profile
Kyle Sherer
SVP, Patient Financial Clearance and Global Profile
Kyle Hicok
Chief Commercial Officer Profile

Similar Companies

Neurotrope

Neurotrope is discovering restorative therapeutics for patients with life-altering neurodegenerative diseases and development disorders. We are a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders. Our experience and passion for novel drug therapies have enabled us to develop a pipeline that includes various treatment approaches for serious and difficult-to-treat diseases such as Alzheimer`s Disease, Fragile X Syndrome and Niemann-Pick Type C

Regulatory Professionals Inc

Regulatory Professionals Inc is a Milpitas, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alnara Pharmaceuticals

Alnara Pharmaceuticals, Inc. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications.

GuideStar Clinical

GuideStar works with hospitals, health systems and physician practices around the country to build, manage and support clinical research programs. From helping incorporate a clinical trial strategy to providing management guidance and support, our service delivery is based on operational and financial best practices to ensure optimal results for research programs.